Influence of alcohol on newly developed metabolic dysfunction-associated fatty liver disease in both sexes: A longitudinal study. Issue 5 (May 2023)

• Record Type: Journal Article
• Authors: Sogabe, Masahiro; Okahisa, Toshiya; Kagawa, Miwako; Ueda, Hiroyuki; Kagemoto, Kaizo; Tanaka, Hironori; Kida, Yoshifumi; Tomonari, Tetsu; Taniguchi, Tatsuya; Okamoto, Koichi; Miyamoto, Hiroshi; Sato, Yasushi; Nakasono, Masahiko; Takayama, Tetsuji
• Is Part Of: Clinical nutrition. Volume 42:Issue 5(2023)
• Page Start: 810
• Page End: 816
• Publication Date: 2023-05
• Subjects: Ages -- Alcohol drinking -- Onset -- Liver diseases -- Sex; Critically ill -- Nutrition -- Periodicals; Diet therapy -- Periodicals; Parenteral feeding -- Periodicals; Enteral feeding -- Periodicals; Enteral Nutrition -- Periodicals; Parenteral Nutrition -- Periodicals; Metabolism -- Periodicals; Diétothérapie -- Périodiques; Alimentation parentérale -- Périodiques; Alimentation entérale -- Périodiques; Nutrition -- Périodiques; Diet therapy; Enteral feeding; Nutrition; Parenteral feeding; Electronic journals; Periodicals; Electronic journals; 615.854
• DOI: 10.1016/j.clnu.2023.03.020
• Languages: English
• ISSNs: 0261-5614

Abstract

Summary: Background & aims: The influence of changes in alcohol consumption on newly developed metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. We investigated the influence of alcohol consumption on newly developed MAFLD in both sexes. Methods: This observational cohort study included 4071 patients who underwent more than two health check-ups between 2015 and 2020 over an interval of more than a year. Generalised estimating equations were used for analyses. Results: At baseline, the rates of drinking and MAFLD between men and women were 72.5% versus 41.7% and 42.2% versus 22.1%, respectively. At the most recent stage, the rates of an increase in alcohol consumption for men and women were 13.3% and 8.7%, respectively, and 311/1192 (26.1%) men and 155/1566 (9.9%) women had newly developed MAFLD. The odds ratio (OR) for drinking in patients with newly developed MAFLD was 0.863 (men) (95% confidence interval [CI], 0.676–1.102, p = 0.237) and 1.041 (women) (95% CI, 0.753–1.439, p = 0.808); the OR for women who drank 140–279.9 g/week was 2.135 (95% CI, 1.158–3.939, p < 0.05) and that for all drinking categories among women was >1. Several non-invasive fibrosis scores were significantly associated with the quantity of alcohol consumption in patients with newly developed MAFLD ( p < 0.005). Conclusions: Alcohol consumption had no significant protective effect against newly developed MAFLD in both sexes, regardless of quantity. Conversely, alcohol consumption ≥140 g/week was a risk factor for newly developed MAFLD in women. The development of liver fibrosis with increased alcohol intake should be considered in patients with MAFLD.